Axsome Therapeutics (AXSM) Earnings Date & Reports

Key Takeaways

• Consensus estimates project Q2 2026 revenue between approximately $221 million and $225 million, reflecting roughly 47% year-over-year growth.
• Analysts expect a net loss per share in the range of -$0.85 to -$0.89, narrowing from -$0.97 reported in the prior-year quarter.
• The June 2026 commercial launch of Auvelity for agitation associated with dementia due to Alzheimer's disease (AD) will contribute its first partial quarter of sales.
• Prescription trends for SYMBRAVO and SUNOSI, along with gross-to-net discount trajectories, will be closely monitored by investors.
• Pipeline catalysts—including multiple Phase III trial initiations and the recently submitted New Drug Application (NDA) for AXS-12 in narcolepsy—add further significance to this report.
• Management's prior guidance that existing cash reserves are sufficient to fund operations into cash-flow positivity will be tested against ongoing commercial and R&D spending levels.

Earnings Context and Why It Matters

This earnings report arrives at a pivotal moment for Axsome Therapeutics. The company recently secured FDA (U.S. Food and Drug Administration) approval for Auvelity in Alzheimer's disease agitation—a first-in-class indication with a multi-billion-dollar peak sales opportunity—and commercially launched the product in June 2026. With three marketed CNS (central nervous system) products now generating accelerating revenue, investors are watching to see whether Axsome can sustain its growth momentum while managing elevated spending on commercialization and research and development (R&D). The Q2 report will offer the first glimpse of how the expanded Auvelity label is translating into real-world demand, making this one of the most consequential quarterly updates in the company's recent history.

Earnings Expectations

For the second quarter of 2026, consensus analyst estimates place revenue between approximately $221 million and $225 million, representing roughly 47% growth from the $150.0 million reported in Q2 2025. The consensus net loss per share is expected to narrow to between -$0.85 and -$0.89, compared with -$0.97 in the same period a year ago.

This follows a mixed Q1 2026 report, in which Axsome posted total net product revenue of $191.2 million—up 57% year-over-year, but slightly below consensus—and a wider-than-expected loss of $1.26 per share, driven by heavy selling, general, and administrative (SG&A) spending tied to pre-launch activities and direct-to-consumer advertising. Despite the earnings miss, shares rose approximately 8% as investors focused on the landmark FDA approval of Auvelity for Alzheimer's disease agitation, awarded breakthrough therapy designation and priority review, and management's updated peak sales outlook of at least $8 billion annually for the Auvelity franchise.

For Q2, analysts will be watching for early signals from the June Alzheimer's agitation launch, continued prescription growth for Auvelity in major depressive disorder (MDD), and the trajectory of SYMBRAVO, which recorded approximately 17,000 prescriptions in Q1 with 36% sequential growth. SUNOSI revenue trends and gross-to-net discount improvements across the portfolio also remain on the radar. Investors will further assess whether cash and cash equivalents of $305.1 million at the end of Q1 remain sufficient to fund operations into cash-flow positivity, as management has guided.

AI Screener

Investors tracking earnings events like Axsome Therapeutics' upcoming Q2 report can benefit from tools that streamline the discovery and monitoring of trade ideas across thousands of equities. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that allows traders and investors to filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those looking to stay ahead of earnings season and broader market moves, the AI Screener offers a practical starting point.

Market Reaction and Investor Sentiment

Axsome shares have delivered a standout performance in 2026, rising approximately 32% year-to-date and more than 129% over the trailing 12 months as of late July. The stock recently traded near $241, reflecting considerable investor optimism around the Auvelity label expansion and the company's advancing neuroscience pipeline. However, sentiment heading into the Q2 report is not without caution. The stock experienced a sharp pullback in early July, dropping from around $250 to the $230 range before partially recovering, suggesting that some investors may be reassessing valuations ahead of the print.

Key risk factors include the pace of the Alzheimer's agitation launch uptake in its inaugural weeks, SYMBRAVO's ability to gain traction against entrenched generic migraine therapies, and whether elevated SG&A expenses—which reached $185.0 million in Q1 alone—continue to pressure the bottom line. With the stock trading well above its 52-week low of $96.09 but below its June 2026 high of $260.19, the Q2 update could serve as a decisive catalyst for near-term direction.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 report, several developments will shape Axsome's trajectory through the remainder of 2026 and into 2027. The most immediate catalyst is the ongoing commercial rollout of Auvelity for Alzheimer's disease agitation. With an expanded sales force of approximately 630 representatives now targeting roughly 68,000 healthcare professionals across primary care, psychiatry, neurology, and geriatric specialties, investors will be watching for early prescription data and payer coverage progress in this new indication.

On the pipeline front, Axsome is advancing an extensive portfolio of late-stage programs. The company expects to initiate a pivotal Phase II/III trial of AXS-05 for smoking cessation and two pediatric Phase III trials of solriamfetol in attention deficit hyperactivity disorder (ADHD) during the second half of the year. Topline results from the ENGAGE Phase III trial of solriamfetol in binge eating disorder are anticipated in the second half of 2026, representing a significant binary event.

Cost management will remain a central theme. SG&A expenses surged 53% year-over-year in Q1, driven by commercialization investments. Investors will look for signs that this spending translates into accelerating revenue growth and that gross-to-net discounts—particularly for SYMBRAVO, which remained in the high-70% range in Q1—begin to improve as payer coverage broadens. Additionally, the FDA's decision on acceptance of the AXS-12 NDA filing for cataplexy in narcolepsy is expected in the near term, marking another potential regulatory milestone.

The company's cash position of $305.1 million as of March 31, 2026, provides a runway that management believes extends to cash-flow positivity. However, continued investment in multiple commercial launches and a broad pipeline means cash burn rates will remain an important metric for investors evaluating the company's financial durability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations